Glycogen Metabolism and Storage Diseases

• Glycogen structure and normal metabolism: Glycogen is a branched polymer of glucose (α-1,4 and α-1,6 glycosidic bonds) serving as the primary carbohydrate reserve in liver and muscle. Normal glycogen metabolism requires coordinated synthesis (via glycogen synthase) and breakdown (via phosphorylase and debranching enzyme) regulated by hormonal signals (insulin, glucagon, epinephrine). When enzyme defects occur, pathological accumulation results in mechanical organ dysfunction and/or depletion causes severe hypoglycemia.

• Hepatic-type GSDs (Types I, III, VI, IX): Predominantly affect glucose homeostasis through impaired hepatic glycogenolysis or gluconeogenesis. Massive hepatomegaly develops from glycogen accumulation, impairing normal liver architecture and synthetic function. Severe fasting hypoglycemia results from inability to mobilize glucose, leading to lactic acidosis, hyperuricemia, and lipemia as compensatory lipolysis and alternative pathways are activated.

• Muscle-type GSDs (Types II, IV, V): Primarily affect skeletal and/or cardiac muscle with glycogen accumulation causing myocyte dysfunction, necrosis, and progressive weakness. Type II (acid maltase deficiency) causes lysosomal glycogen accumulation with distinctive vacuolar myopathy. Types V and VII cause energy depletion during muscle contraction, resulting in exercise intolerance and rhabdomyolysis.

• Type IV (branching enzyme deficiency): Produces abnormal glycogen structure with fewer branch points and longer outer chains, creating hepatotoxic deposits that trigger fibrosis and cirrhosis, distinguishing it pathophysiologically from other types.

• Metabolic consequences: Blocked breakdown pathways shunt glucose precursors toward lactate production (lactic acidosis), glycerol-3-phosphate (hypertriglyceridemia), and purine synthesis (hyperuricemia with gout), creating multi-organ metabolic derangements beyond glycogen storage.

• Type I (Von Gierke disease) — most common severe form: Presents in infancy (3-4 months) with severe fasting hypoglycemia, hepatomegaly (can reach enormous proportions), lactic acidosis, hyperuricemia with gout (unusual in young children), severe hypertriglyceridemia (eruptive xanthomas), and characteristic "doll-like" facial features with fat cheeks and short stature. Recurrent infections and bleeding diathesis occur due to neutrophil dysfunction and platelet abnormalities.

• Type II (Pompe disease) — infantile form: Presents at 2-3 months with severe hypotonia, developmental delay, massive cardiomegaly with heart failure (pathognomonic finding), hepatomegaly, and characteristic "floppy baby" appearance. Death typically occurs by age 2 from cardiorespiratory failure if untreated. Late-onset form presents with progressive proximal muscle weakness in childhood/adulthood without cardiac involvement.

• Type III (Cori disease): Presents similarly to Type I with hepatomegaly and hypoglycemia but generally milder and with better prognosis. Fasting hypoglycemia less severe than Type I; some patients have myopathy with progressive muscle weakness.

• Type IV (Andersen disease) — branching enzyme deficiency: Presents with hepatomegaly, hepatic dysfunction, and progressive cirrhosis typically by age 3-5 years. GI symptoms (failure to thrive, diarrhea), ascites, splenomegaly, and hepatic encephalopathy mark progression to liver failure. Some patients have neuromuscular involvement.

• Type V (McArdle disease) — muscle phosphorylase deficiency: Adolescent/young adult onset with exercise intolerance, painful muscle cramps, and myoglobinuria (dark urine) after exertion. Second wind phenomenon (improvement with continued activity) is pathognomonic. Risk of acute rhabdomyolysis with renal failure with intense exercise. Normal fasting glucose distinguishes from hepatic types.

• Type VI and IX (mild hepatic types): Hepatomegaly and growth delay in childhood but generally good prognosis with spontaneous improvement in adolescence. Mild fasting hypoglycemia possible.

• Type VII (phosphofructokinase deficiency): Similar presentation to Type V with exercise intolerance and myoglobinuria; also causes hemolytic anemia (unique feature distinguishing from Type V).

• Clinical suspicion and fasting challenge test: History of hypoglycemia during fasting/illness, hepatomegaly in infancy, or exercise intolerance with myoglobinuria raises GSD suspicion. Fasting challenge (6-12 hours) showing severe hypoglycemia (<40 mg/dL) with elevated lactate, uric acid, and triglycerides is classic for Type I but dangerous—must monitor closely or use shorter fast.

• Enzyme assays and genetic testing: Gold standard diagnosis involves tissue-specific enzyme assays (liver biopsy for hepatic types, muscle/fibroblasts for muscle types, WBC/fibroblasts for specific deficiencies). Modern approach increasingly uses genetic sequencing (DNA mutation analysis) which is non-invasive and definitive but must still correlate with clinical phenotype.

• Metabolic markers during fasting/ischemic exercise test: Type I shows severe hypoglycemia with lactic acidosis disproportionate to other GSDs. Type V shows flat blood lactate during ischemic forearm exercise (muscle cannot produce lactate without glycogen phosphorylase) while ammonia rises markedly—pathognomonic finding. Type II shows no fasting hypoglycemia but CK markedly elevated in infantile form.

• Imaging findings: Hepatomegaly on ultrasound/CT present in most hepatic types; homogeneous, echogenic liver common. Type II shows massive cardiomegaly on chest X-ray/echo with ejection fraction <20% in infantile form. Type IV shows cirrhotic liver changes with fibrosis on imaging.

• Tissue biopsy and electron microscopy: Liver biopsy shows PAS-positive, diastase-resistant glycogen accumulation; electron microscopy distinguishes between normal glycogen (Type I, III) and abnormal structures (Type IV) or lysosomal accumulation (Type II).

• Important diagnostic pearls: GSD should be suspected in any infant with hepatomegaly + hypoglycemia, cardiomegaly in an infant, or unexplained exercise intolerance with myoglobinuria. Neonatal screening programs now include some GSDs. Genetic counseling essential—all GSDs autosomal recessive except Type IX (X-linked).

• Type I (Von Gierke) — frequent feeding protocol: Continuous nasogastric feeding overnight with uncooked cornstarch (provides 8-12 hour glucose buffer via slow digestion) or glucose polymer solutions is first-line to prevent fasting hypoglycemia. Frequent daytime meals (every 3 hours) with carbohydrates essential. Strict avoidance of fasting and illness-related missed meals. Allopurinol (or febuxostat) for hyperuricemia to prevent gout and renal urate nephropathy.

• Type II (Pompe disease) — enzyme replacement therapy: Imiglucerase IV infusion (enzyme replacement therapy) is disease-modifying and must be started early in infantile form to prevent death—dramatically extends lifespan when initiated before cardiac/respiratory compromise. Late-onset forms benefit but with slower progression. Supportive care (mechanical ventilation, cardiac support) essential while awaiting enzyme levels to take effect. Gene therapy emerging but not yet standard.

• **Types III

Enzyme-to-eponym mapping (the single most tested item)

• Type I = von Gierke = glucose-6-phosphatase: the only defect that blocks the final common step of both glycogenolysis and gluconeogenesis — which is why lactate, uric acid, and triglycerides all rise while glucose falls. Glucagon (or galactose/fructose) fails to raise blood glucose.
• Type II = Pompe = lysosomal acid α-glucosidase (acid maltase): the defect is inside the lysosome, not in the cytosolic pathway, so blood glucose is normal — "*Pompe trashes the pump*." Cardiomegaly plus floppy infant is the stem.
• Type III = Cori/Forbes = debranching enzyme: limit dextrins accumulate; phosphorylase still clips outer chains, so hypoglycemia is milder and lactate and uric acid are typically normal — the cleanest discriminator from von Gierke.
• Type V = McArdle = myophosphorylase (muscle-specific): liver phosphorylase is intact, so fasting glucose is normal. Second wind after several minutes of activity (fatty acid and hepatic glucose delivery) is the buzzword; ischemic forearm testing shows no rise in lactate with an exaggerated ammonia rise.
• Type VII (PFK-1): mimics McArdle plus hemolytic anemia, since erythrocytes depend on the same isozyme for glycolysis.

Best next steps

• Infant with cardiomegaly, hypotonia, high CK, normal glucose → confirm Pompe by acid α-glucosidase activity (dried blood spot) with genetic confirmation, then start enzyme replacement immediately; ACMG guidance and the federal RUSP newborn screening panel both emphasize that outcomes depend on treatment before irreversible cardiorespiratory damage.
• Infant with hepatomegaly + fasting hypoglycemia + lactic acidosis → maintain euglycemia with frequent feeds and cornstarch per ACMG GSD I guidance; long-term surveillance for hepatic adenoma with malignant transformation and renal disease.
• McArdle: sucrose or glucose before exertion; avoid maximal isometric exercise; treat rhabdomyolysis with aggressive IV fluids.

Distractors to avoid

• Pompe ERT is alglucosidase alfa, not imiglucerase (that agent treats Gaucher disease).
• Inheritance is autosomal recessive except X-linked phosphorylase kinase (type IX).
• Hepatic glycogen is PAS-positive but digested by diastase; PAS-positive diastase-resistant globules point to α1-antitrypsin deficiency.